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The interfollicular epidermis is continuously renewed, thanks to a regulated balance between proliferation and differentiation.
The DNp63 transcription factor has a key role in the control of this process. It has been shown that DNp63 directly regulates
Runt-related transcription factor 1 (RUNX1) transcription factor expression in mouse keratinocytes. The present study showed
for the ﬁrst time that RUNX1 is expressed in normal human interfollicular epidermis and that its expression is tightly regulated
during the transition from proliferation to differentiation. It demonstrated that DNp63 directly binds two different RUNX1
regulatoryDNAsequencesandmodulatesRUNX1expressiondifferentiallyinproliferativeordifferentiatedhumankeratinocytes.
It also showed that the regulation of RUNX1 expression by DNp63 is dependent on p53 and that this coregulation relies on
differential binding and activation of RUNX1 regulatory sequences by DNp63 and p53. We also found that RUNX1 inhibits
keratinocyte proliferation and activates directly the expression of KRT1, a critical actor in early keratinocyte differentiation.
Finally,wedescribedthatRUNX1 expression, similartoDNp63andp53,wasstronglyexpressedanddownregulatedinbasalcell
carcinomas andsquamouscellcarcinomas respectively.Takentogether,thesedatashedlight ontheimportance oftightcontrol
of the functional interplay between DNp63 and p53 in regulating RUNX1 transcription factor expression for proper regulation of
interfollicular epidermal homeostasis.
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The epidermal homeostasis relies on proper control of
proliferation and differentiation programs within epidermal
cells. This differentiation process requires a precise coordina-
tion of the molecular events maintaining functional epidermis.
p63 belongs to the p53/p63/p73 family of transcription factors
(TFs)thatshareaconservedDNA-bindingdomainandsimilar
DNAtargetsitesin regulatorysequences ofeukaryoticgenes.
p63 is essential for the development and maintenance of
pluristratiﬁed epithelia, including epidermis.
1 Mice lacking p63
display profound defects in epidermis formation and died
shortly after birth due to dehydration.
2,3 p63 is also critical for
postnatal proliferation in basal keratinocytes and epidermal
differentiation.
4 Several p63 proteins have been described,
resulting from two distinct promoters, TAp63 and DNp63, and
from alternative mRNA splicing at the 30 end of the gene.
5
The major isoform present in adult human epidermis is
DNp63a, expressed at high levels in the basal layer and
at lower levels in suprabasal keratinocytes.
6 p63 is
overexpressed in many epithelial tumors, namely basal cell
carcinoma (BCCs) and squamous cell carcinomas (SCCs)
7
and is mutated in 8% of head and neck SCCs.
8
Runt-related transcription factor 1 (RUNX1) has been
identiﬁed among the direct p63 transcriptional targets in
epidermis.
9–11 RUNX1 belongs to the RUNX TFs family,
which have an essential role in the balance between cell
proliferation and differentiation in animal tissue development.
RUNX family genes share a region, the Runt domain, which,
with its partner subunit core-binding factor beta (CBFb), is
responsible for speciﬁc DNA binding and heterodimerization
and activates or represses transcription through the recruit-
ment of various coactivators and corepressors depending on
the cellular context.
12 The RUNX genes also have a complex
role in cancer, acting aseither tumorsuppressors or dominant
oncogenes.
13 RUNX1 is a master regulator in the
development, growth and differentiation of hematopoietic,
14
muscular
15 and nerve cells.
16 In mouse skin, RUNX1
expression was found in hair follicles, and its speciﬁc
disruption in mouse epidermal cells impaired hair follicle
homeostasis and long-term differentiation.
17–19 In human
skin, RUNX1 is also highly expressed in hair follicles and
involved in KAP5 regulation, a keratin-associated protein
expressed in the cuticle layer of anagen hair follicles.
20
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www.nature.com/cddisTo date, RUNX1 function has never been explored in
human interfollicular epidermis. We therefore investigated
RUNX1 expression pattern in human normal skin, revealing
expression in the interfollicular epidermis. Our data shed light
on the complex coregulation of RUNX1 by DNp63 and p53,
leading to a role for RUNX1 in the switch from proliferation to
differentiation by repressing the cell cycle and activating a
marker of early keratinocytes differentiation. It also showed
that RUNX1 expression is dysregulated in human cutaneous
BCCs and SCCs.
Results
RUNX1 is expressed in normal human interfollicular
epidermis and tightly regulated in primary keratinocytes.
RUNX1 gene expression is restricted to hair follicles in
mouse skin
18 and is strongly expressed in human hair
follicles.
20 We therefore investigated whether RUNX1 was
also expressed in human interfollicular epidermis, using a
RUNX1-speciﬁc antibody on sections of normal human skin
(Figure 1). As previously described, a strong RUNX1
expression was observed in cell nuclei from both the outer
root sheath and the inner root sheath of human anagen hair
follicles (Figures 1a and b). RUNX1 was also detected at
lower but consistent levels in interfollicular epidermis:
most of the basal keratinocytes exhibited speciﬁc nuclear
labeling (Figures 1c and d) that decreased in suprabasal
layers, when compared with negative control (Figure 1e).
This staining pattern was observed in foreskin, facial, breast
and abdominal skin.
To investigate RUNX1 expression more precisely in normal
human interfollicular keratinocytes, we next used a model of
Ca
2þ-induced differentiation of human primary keratino-
cytes (HPK) in culture, monitored by induction of keratin1
(Figure 2a), keratin10 (Figure 2b), involucrin (Figure 2c)
and loricrin (Figure 2d), widely used markers of epidermal
differentiation. At both mRNA (Figure 2e) and protein
(Figure 2f) levels, RUNX1 was tightly regulated along the
Figure 1 RUNX1 expression in human skin. Sections of parafﬁn-embedded normal human facial skin stained with anti-RUNX1 polyclonal (a–d) or control rabbit IgG (e)
antibodies. The arrow shows RUNX1 nuclear labeling in longitudinal (a) and transversal (b) sections of a hair follicle. In the interfollicular epidermis (c and d), RUNX1 is
essentially expressed in keratinocytes of the basal layer and its expression strongly decreases in suprabasal layers. The square in (c) represents the area of magniﬁcation
shown in the (d). Scale bar¼50mm
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Cell Death and Diseasetransition from proliferation to differentiation: in keratinocytes
fromthreedifferentdonors,RUNX1wasstronglyexpressedin
semi-conﬂuent cells, then gradually declined when cells
reached conﬂuence and was weakly but reproducibly reacti-
vated at the onset of differentiation. So, RUNX1 is expressed
in human interfollicular epidermis and tightly regulated during
the transition from proliferation to differentiation.
DNp63 modulates RUNX1 expression differentially in
proliferative or differentiated human keratinocytes via
two DNA regulatory sequences. RUNX1 has been
recently identiﬁed by chromatin immunoprecipitation (ChIP)
screens as a direct transcriptional target gene of DNp63 in
subconﬂuent mouse keratinocytes
9 and HaCaT cell line.
10,11
These studies revealed that DNp63 binds an intronic
region and one part of exon 1 of the RUNX1 gene that
are highly conserved between species, and that p63 is able
to transactivate Runx1 expression. ChIP-quantitative PCR
(QPCR) conﬁrmed that RUNX1 exon 1 and intron 5
sequences are indeed signiﬁcantly bound by p63 in HPK
(Figure 3a).
The fact that p63 can bind two distinct regulatory DNA
sequences of RUNX1 gene suggested a more complex
modulation of RUNX1 expression in human than that was
previously proposed in mouse.
9 Because RUNX1 expression
is tightly regulated at the transition from proliferation
to differentiation (Figures 2e and f) and DNp63 can exert
separate control over keratinocyte proliferation and differen-
tiation,
4 we hypothesized that RUNX1 expression can be
differentially modulated by DNp63 in cells that stopped
proliferation and began a differentiation program, versus still
nonconﬂuent proliferating keratinocytes (Materials and
Methods). RUNX1 expression was analyzed after DNp63-
speciﬁc inactivation by RNA interference in these human-
differentiated or proliferative keratinocytes. DNp63 silencing
was very efﬁcient in both proliferating and differentiated
keratinocytes at the mRNA (Figure 3b, left panel) and protein
(Figure 3c) levels. When DNp63 was speciﬁcally knocked
down in proliferative cells, RUNX1 expression was signiﬁ-
cantly decreased (Figure 3b right panel and 3c left panel),
suggesting that DNp63 positively regulates RUNX1 expres-
sion in proliferative human keratinocytes, as also observed in
proliferative mouse keratinocytes.
9 In contrast, reducing
DNp63 expression in differentiated keratinocytes strongly
increasedRUNX1expression(Figures3bandc,rightpanels),
showing thatDNp63negativelycontrolsRUNX1 expressionin
Figure 2 RUNX1 expression in cultured human keratinocytes. (a–e) Keratin1 (a), keratin10 (b), involucrin (c), loricrin (d) and RUNX1 (e) transcripts were quantiﬁed by
QPCR in semi-conﬂuent, conﬂuent or Ca
2þ-induced differentiating keratinocyte cultures (D1, D2, D3) from three different donors (HPK1, HPK2, HPK3). Mean expression is
indicatedfor (a–d);detailedexpression for eachculture isgivenfor (e). (f)RUNX1protein expression was analyzedfromkeratinocyteculturesestablishedatthe samestages
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Cell Death and Diseasecells that stopped proliferating and began differentiating.
Taken together, these data showed that DNp63 differentially
modulates RUNX1 expression depending on the proliferative
or differentiation-committed state of human keratinocytes.
We then postulated that this differential regulation of
RUNX1 expression could be linked to DNp63 differential
bindingontoRUNX1regulatoryDNAsequences.ChIP-QPCR
was therefore performed in HPK from three different donors in
a proliferative or 3-day differentiated state. p63 was system-
atically bound (1.5–4-fold relative to the three donors) to the
RUNX1 intron 5 sequence in both proliferative and differ-
entiated keratinocytes (Figure 3d, left panel), but was able to
bind exon 1 only in differentiated cells (1.6–2-fold; Figure 3d,
right panel).
Overall, these results strongly suggest that DNp63
differentially regulates RUNX1 expression along the transition
from proliferation to differentiation by differential binding of its
regulatory sequences, highlighting the complexity of direct
RUNX1 transcriptional regulation by DNp63 in human
interfollicular keratinocytes.
p53 binds the same RUNX1 regulatory sequences
and cooperates with DNp63 for regulation of RUNX1
expression. We postulated that other p53 family members,
which are able in some speciﬁc cases to directly regulate the
same transcriptional target genes, in either a similar or a
converse way,
21,22 could likewise modulate the DNp63 action
on RUNX1 regulation by binding its regulatory sequences.
We therefore questioned whether the long p63 isoform,
TAp63, as well as the p53 and/or p73 TFs could regulate
RUNX1 expression in human interfollicular keratinocytes,
given that they are expressed along the transition from
proliferation to differentiation (data not shown).
22 However,
modulating TAp63 or p73 expression in primary keratino-
cytes did not affect RUNX1 expression levels (data not
shown). In contrast, p53 was found to cooperate with DNp63
for RUNX1 regulation in HPK (Figure 4). Silencing of p53
alone in human keratinocytes had no effect on RUNX1
expression (Figure 4a). However, when both p53 and
DNp63 expression was decreased by small interfering RNA
(siRNA), RUNX1 expression was not repressed anymore
Figure 3 DNp63 can bind RUNX1 intron 5 and exon 1 DNA sequences and regulates its expression differentially in proliferating and differentiated keratinocytes.
(a) Human RUNX1 gene map (upper panel) showing the exon–intron structure: arrows represent the DNA regions in exon 1 and intron 5 ampliﬁed by QPCR after ChIP
experiments (lower panel). p63-ChIP assays were performed in three cultures of differentiated HPK. Enrichment of RUNX1 exon 1 and intron 5 regions was analyzed in
comparison with a control promoter region. (b) DNp63 (left panel) and RUNX1 (right panel) transcript levels were quantiﬁed by RT-QPCR after treatment of proliferative or
differentiated HPK with control or DNp63 siRNA. (c) p63 and RUNX1 protein levels were assessed by immunoblotting after treatment of proliferative (left panel) or
differentiated (right panel) HPK with control or DNp63 siRNA. (d) p63-ChIP assays were performed in proliferative or 3-day differentiated HPK from three different donors
(HPK1, HPK2, HPK3). Enrichment of the RUNX1 intron 5 (left panel) and exon 1 (right panel) regions was analyzed in comparison with a control promoter region by QPCR
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Cell Death and Diseasein proliferative keratinocytes (Figure 4b left panel and 4c
upper panel), compared with what was observed after DNp63
inhibition alone (Figure 3b right panel and 3c left panel).
So DNp63 needs p53 expression for RUNX1-positive
regulation in proliferative keratinocytes. However, in differ-
entiated keratinocytes, inhibition of both p53 and DNp63 did
not disturb the DNp63 silencing-mediated effect on RUNX1
expression (compare Figure 4b right panel with 3b right panel
and Figure 4c lower panel with Figure 3c right panel). These
results are conﬁrmed by DNp63 silencing in the human
HaCaT keratinocyte cell line (Figure 4d), known to express a
mutated form of p53 that is transcriptionally inactive.
23
Indeed, RUNX1 expression was not signiﬁcantly modiﬁed
in proliferative HaCaT cells when DNp63 expression was
decreased, conversely to what was observed in HPK that
express a functional p53 protein (compare Figures 4d
with 3b). These results were strengthened by studying
RUNX1 expression proﬁle in HaCaT cells: RUNX1 levels
signiﬁcantly decreased between proliferation and 1 day of
differentiation but did not signiﬁcantly increase again
between 1 and 3 days of differentiation, conversely to what
was observed in normal HPK (compare Figures 4e with 2e
and f). Thus, a functional p53 protein is necessary to properly
regulate RUNX1 expression, in cooperation with DNp63,
during the switch from proliferation to differentiation.
We conﬁrmed by ChIP-QPCR that the p53 role in RUNX1
regulation depends on direct binding of p53 protein onto
RUNX1 intron 5 and exon 1 (1.5–3.5-fold relative to the
different donors; Figure 5a), whatever the state (proliferative
or differentiated) of HPK.
To further investigate the speciﬁc role of each of the
two DNA regulatory sequences of RUNX1 in DNp63 and p53
regulation, the parts of RUNX1 exon 1 or intron 5 that are
bound in vivo by these two TFs were individually cloned into a
luciferase reporter vector. The p53 and DNp63 overexpres-
sion effect (Figure 5b, left panel) on RUNX1 exon 1 and intron
5 transcriptional regulation was then analyzed by transactiva-
tion assays and revealed opposite transcriptional effects on
the RUNX1 gene; p53 overexpression signiﬁcantly activated
luciferase activity via RUNX1 intron 5 without inﬂuencing
exon 1 activity, whereas DNp63 overexpression did not affect
intron 5 regulation but signiﬁcantly repressed luciferase
Figure 4 p53 cooperates with DNp63 to regulate RUNX1in HPK. (a) RUNX1 transcriptlevels was quantiﬁedby RT-QPCRafter treatment of proliferativeor differentiated
HPKwithcontrolorp53siRNA.Theeffectofp53siRNAonp53expressionwasshowninFigure2b.(b)p53,DNp63andRUNX1transcriptlevelswerequantiﬁedbyRT-QPCR
after treatment of proliferative (left panel) or differentiated (right panel) HPK with control or p53 and DNp63 siRNA. (c) RUNX1 protein level was assessed by WB 48h after
treatmentof proliferative(upper panel) or differentiated(lower panel) HPK with both p53 and DNp63 siRNA. (d) DNp63 (left panel) and RUNX1 (right panel) transcripts levels
were quantiﬁed by RT-QPCR after treatment of proliferative or differentiated HaCaT cells with control or DNp63 siRNA. (e) RUNX1 transcripts were measured by QPCR at
different stages of the HaCaT cell cultures (left panel). Involucrin (INV) and RUNX1 proteins expression was assessed by immunoblotting at different stages of the HaCaT
culture (right panel)
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Cell Death and Diseaseactivity via the RUNX1 exon 1 (Figure 5b, right panel).
Moreover, additional experiments showed that DNp63 was
able to compete with p53 on RUNX1 intron 5 (Figure 5c), in
agreement with in vivo ChIP experiments. These data
suggested that DNp63 could repress RUNX1 expression by
binding to its exon 1 regulatory sequence, whereas
p53 could induce RUNX1 expression by binding to its intron
5 DNA sequence.
RUNX1 modulates keratinocyte proliferation and directly
regulates KRT1 gene expression. As DNp63 has a critical
function in the regulation of entry into differentiation and is
involved in RUNX1 coregulation along with p53, we
investigated whether RUNX1 may also have a key role in
the regulation of proliferation and differentiation processes in
human interfollicular epidermis.
To this end, the RUNX1 role in proliferation was explored in
proliferating HPK. RUNX1 overexpression under exponential
growth conditions led to a strong increase in mRNA (data not
shown) and protein RUNX1 levels (Figure 6a, left panel)
associated with a signiﬁcant decrease in cell number
compared with an empty vector control (Figure 6a, right
panel). Conversely, RUNX1 knockdown (Figure 6b, left
panel), by transfecting a validated speciﬁc siRNA,
24 signiﬁ-
cantly increased cell number (Figure 6b, right panel). This
modiﬁcation of cell number is due to a higher proliferation rate
(Figure 6c). In fact, RUNX1 inhibition by siRNA increased the
percentage of BrdU-positive keratinocytes (R2 region) and
concomitantly decreased the percentage of keratinocytes in
the G1 phase (R1 region) (Figure 6d, left panel). This
signiﬁcant RUNX1 effect on cell cycle modulation was
consistently found in four independent experiments using
keratinocytes from various donors (Figure 6d, right panel).
Interestingly, we found that RUNX1 depletion by siRNA led to
a signiﬁcant decrease of p21 expression, a negative regulator
of cell cycle, as well as to a signiﬁcant increase of proliferation
Figure 5 Functional interplay between DNp63 and p53 to regulate RUNX1 expression. (a) p53-ChIP assays were performed in proliferative or 3-day differentiated HPK
from three different donors (HPK1, HPK2, HPK3). Enrichment of the RUNX1 intron 5 (left panel) and exon 1 (right panel) regions was analyzed in comparison with a control
promoterregion by QPCR. (b) p53 and DNp63 (left panels) protein levels were analyzedby immunoblotting after 48h transfectionof pCMV-p53and pcDNA3-DNp63 vectors
or their respective empty vectors in HEK293 cells. Results shown are representative of two independent experiments. The right panel shows reporter gene assays for part of
exon 1 and intron 5 of RUNX1 cloned in pGL3 promoter after overexpression of p53 or DNp63 proteins. Four independent experiments were performed. (c) Competition
luciferase assays were performed with increasing concentration (200 or 400ng) of pcDNA3-p63 for competition with p53 on RUNX1 intron 5 (left panel) and with increasing
concentration (200 or 400ng) of pCMV-p53 for competition with DNp63 on RUNX1 exon 1 (right panel)
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Cell Death and Diseasecell nuclear antigen (PCNA) and Ki67, two well-known
markers of proliferation (Figure 6e). Taken together, these
data indicate that RUNX1 is a negative regulator of cell
proliferation in cultured human keratinocytes.
We also investigated whether RUNX1 has a role in
regulating the early differentiation process, as RUNX1
and its regulator DNp63 are both expressed in the ﬁrst
differentiated layers of the human epidermis. A bioinformatic
screen for RUNX1 binding sites in promoter regions of 27
genes selected for their strong expression in human granular
and spinous keratinocytes
25 revealed highly conserved
RUNX1 binding sites (score40.9) in the promoter sequences
of 3 genes. One site in the promoter ( 577 to  563) and
another in the ﬁrst exon (þ186 to þ190) was identiﬁed for
KRT1 (encoding keratin1), whereas TGM1 and LOR (respec-
tively encoding transglutaminase1 and loricrin) exhibited only
one site ( 508 to  494 and  323 to  309, respectively).
As the presence of a consensus binding site is merely
suggestive of a possible regulation, RUNX1 depletion was
conducted by siRNA transfection. It led to reduction of KRT1
and LOR mRNA levels by 430% whereas TGM1 mRNA was
not signiﬁcantly modiﬁed (Figure 7a), showing that KRT1 and
LORareRUNX1downstreamtargetsinhumankeratinocytes.
To investigate whether RUNX1 directly regulates KRT1 and
LOR expression, the effect of RUNX1 and/or its cofactor
CBFb on the promoter regulation of these two genes was
examined by luciferase assay (Figure 7b). RUNX1 over-
expression did not modify the levels of LOR reporter activity,
whereas it reproducibly and signiﬁcantly increased KRT1
reporter activity. When one of the two potential RUNX1
binding sites was deleted, basal luminescence intensity and
induced luciferase activity after RUNX1 and/or CBFb trans-
fection were abolished. Taken together, these ﬁndings
indicate that RUNX1 positively regulates KRT1 expression
by directly binding to its promoter. Overexpression or
inhibition of RUNX1 in HPK led to a correlated regulation of
endogenous KRT1 protein (Figure 7c), conﬁrming the positive
regulation exerted by RUNX1 on KRT1 protein. Finally,
ChIP-QPCR experiments using three different anti-RUNX1
antibodies showed strongly enriched KRT1 promoter
sequences in the immunoprecipitated fraction, (3- to 13-fold)
whereas LOR and TGM1 target sequences were not enriched
Figure 6 RUNX1 represses humankeratinocyte proliferation. (a) RUNX1 overexpression using pCMV-RUNX1 was veriﬁed by western blotting (left panel) comparedwith
anemptyvectorandcellnumbers(rightpanel)weredetermined.Errorbarsaremean þ/ S.D.oftriplicatesamplesfromonerepresentativeexperiment.(b)RUNX1mRNA
(upperleftpanel)andprotein(lowerleftpanel)levelsweremeasuredafterRUNX1silencingbyansiRNAtargetingRUNX1versusacontrolnon-targetingsiRNAinproliferating
keratinocytes and cell numbers were determined (right panel). (c) Proliferation study using BrdU incorporation assay was performed in triplicate in three independent
experiments with different donors. (d) Cell cycle analysis of siRUNX1-transfected keratinocytes shows percentages of cell cycle phases (R1¼G0/G1, R2¼S, R3¼G2/M,
leftpanel).Dotplotsillustrateonerepresentativeexperiment.Thegraph(rightpanel)showsthepercentageof stainedRUNX1siRNA-treatedkeratinocytes/thepercentage of
stainedcontrolsiRNA-treatedkeratinocytes.(e)p21,PCNAandKi67transcriptslevels werequantiﬁedbyRT-QPCR24h aftertreatmentof proliferatingprimarykeratinocytes
with control or RUNX1 siRNA
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Cell Death and Disease(Figure 7d), in agreement with the above expression analysis
and reporter assay data. Overall, these results demonstrate
that, in cultured human keratinocytes, RUNX1 directly binds
the KRT1 promoter sequence and validate KRT1 as a direct
RUNX1 transcriptional target in these cells.
Taken together, these data showed that RUNX1, tightly
regulated by DNp63 and p53 during the transition from
proliferation to differentiation in human interfollicular kerati-
nocytes,isabletomodulateboth theproliferationprocessand
the expression of early differentiation markers.
RUNX1 expression is dysregulated in human skin
carcinomas. BCCs and SCCs are the two commonest
nonmelanoma cancers of epithelial origin in the skin. BCCs
are derived from or closely related to long-term resident
progenitor cells of the interfollicular epidermis,
26 whereas
SCCs might originate from both hair follicles and interfolli-
cular epidermis.
27 Missense mutations in the tumor suppres-
sor gene p53 are a common genetic feature of these tumors,
as a result of a complex sequence of events initiated by
exposure to UV light.
28 BCCs and SCCs are also character-
ized by DNp63 protein upregulation.
7,29 As RUNX1 expres-
sion is tightly regulated by differential interplay between p53
and DNp63, we analyzed RUNX1 expression by immuno-
chemistry in a panel of BCCs and SCCs (Figure 8). All BCCs
overexpressed RUNX1, compared with RUNX1 expression
level in the basal layer of surrounding epidermis (Figure 8a),
but to varying degrees: 3/18 showed low RUNX1 expression
with o10% immunostained cells, 6/18 had a moderate
immunostaining with 40–80% positive cells, and 9/18 showed
a high RUNX1 expression with over 80% immunostained
cells (Figure 8c). By contrast, only 9 out of 15 SCCs
presented RUNX1 immunostaining (Figures 8b and c).
The majority exhibited a low to moderate RUNX1 staining.
In conclusion, these data support the contention that
RUNX1 is dysregulated in nonmelanoma skin tumors and
is expressed at higher levels in BCCs than in SCCs.
Discussion
The present study shows for the ﬁrst time that RUNX1 is
expressed in human interfollicular epidermis, while being
restricted to hair follicles in mouse skin.
18 These results are in
line with the strong DNp63 expression in human interfollicular
epidermis, shown as a direct transcriptional regulator of
RUNX1.
9–11 We have also demonstrated that RUNX1 is
tightly regulated by a complex mechanism involving
DNp63 and p53, and control cell proliferation and onset of
differentiation.
Among the members of the p53/p63/p73 TFs family, TAp63
and the short (DN) and long (TA) isoforms of p73 are also
expressed in human interfollicular keratinocytes.
22 However,
the DNp63 isoform was shown as the main p63 mediator
regulating the switch from proliferation to differentiation,
whereas several studies involved TAp63 and p73 isoforms
in the development of the granular and horny layers.
1,4,30,31
These data agree with our results, suggesting that TAp63 and
p73 are dispensable for RUNX1 expression in human
interfollicular epidermis.
Only p53 cooperates with DNp63 during the transition
from proliferation to differentiation of human interfollicular
keratinocytes. DNp63 would have a key role for the entry into
differentiation by inhibiting RUNX1 expression, whereas, in
proliferating keratinocytes, p53 would overcome the DNp63-
negative regulatory effect to activate RUNX1. Our results
reinforce and complete the study conducted in human
keratinocytes by Truong et al.
4 that clearly demonstrated
a role for p53 in epidermal proliferation but not in the
Figure 7 RUNX1 directly regulates KRT1 expression. (a) RUNX1, KRT1, LOR and TGM1 transcripts were assessed by RT-QPCR 24h after transfection by RUNX1 or
control siRNA. (b) Reporter gene assays were done for LOR promoter and full or partially deleted KRT1 promoters. (c) RUNX1 and KRT1 expression was assessed by
western blotting 48h after pCMV-RUNX1 or RUNX1 siRNA transfection in primary keratinocytes. (d) ChIP-QPCR assays using various anti-RUNX1 antibodies or control Ig
showed the enrichment of KRT1, LOR, TGM1 promoter and control intragenic sequence. For RUNX1 pAb AB1, results are means þ/ S.D. from three independent
experiments
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Cell Death and Diseasedifferentiation process. Moreover, the importance of p53 for
regulationbyp63ofanotherTF,Krueppel-likefactor4(KLF4),
was recently shown in proliferative epidermal cells.
32 Collec-
tively, our data of expression, ChIP and reporter assays
allows us to propose a model for the regulation of RUNX1
expression: in proliferating keratinocytes, both DNp63 and
p53 would bind RUNX1 intron 5, that in turn leads to RUNX1
activation by p53 via this positive regulation element.
In keratinocytes that reach conﬂuence, stop proliferating and
begin differentiating, DNp63 would join p53 onto RUNX1
exon1regulatorysequencethathasforconsequenceRUNX1
repression by DNp63. Therefore, the tight control of RUNX1
expression by this functional interplay between the two TFs
DNp63 and p53 could lead to a ﬁne regulation of downstream
molecular events to allow a proper transition from proliferation
to differentiation in human interfollicular keratinocytes.
Indeed, we showed that the tight regulation of RUNX1
expressionleadstotheregulationofbothproliferationandearly
differentiation. RUNX1 inhibits human interfollicular keratino-
cyte proliferation. This antiproliferative effect seems to be
speciﬁc to this cell type, as RUNX1 is known to be a positive
regulator of G1-to-S cell cycle progression in hematopoietic
tissue,
14neuralprogenitors
16and,morerecently,inmousehair
follicle stem cells.
17 However, a strong correlation between
negative cell cycle regulators and RUNX1 expression was
observed in endometrial carcinoma,
33 underlying the complex-
ity of RUNX1 cell growth regulation, in line with the fact that
RUNX1 can act as both a transcriptional repressor and
activator. We also showed that RUNX1 could activate the
KRT1 gene inhuman keratinocytes through directbinding toits
promoterregion. KRT1 inductionisoneofthe earliesteventsin
keratinocyte differentiation, as it occurs in basal keratinocytes
that have ceased mitotic activity.
34 These results are even
more interesting as DNp63 is also responsible for KRT1
regulation via c-Jun N-terminal kinase/AP1 activation.
35 Thus,
RUNX1 appears to have a key role together with DNp63 in the
switch from proliferation to differentiation in the basal layer, by
downregulating the cell cycle and inducing early differentiation
markers such as KRT1.
Finally, we showed that RUNX1 expression is dysregulated
in the two most widespread nonmelanoma skin cancers
of epithelial origin, BCCs that are locally destructive but
metastasizes only exceptionally, and SCCs with high meta-
static potential.
36 RUNX1 seems to be globally more
expressed in BCC cells, which are phenotypically closed to
basal proliferating keratinocytes, than in SCC cells, which
appear as more differentiated. This RUNX1 pattern is not
identical with that of DNp63 expression, although DNp63 is
also more strongly expressed in BCCs compared with SCCs
(data not shown;
7,29,32).Conversely, our data andthoseof the
literature show a better correlation between RUNX1 and p53
expression. As p53 is mutated and highly expressed in SCCs
(whereas expression is lower in BCCs
29,32), it could lead to a
lack of RUNX1 activation in differentiated SCC cells, which in
turn would be silenced by DNp63 overexpression, according
to our proposed model. This model is strengthened by the fact
that clusters of cells overexpressing a mutated form of p53,
considered as potential precursors of SCCs, can be detected
in the interfollicular epidermis before the skin tumors arise;
37
and that the negative regulation of KLF4, another target of
p63, is subverted by p53 mutations commonly found in
SCC.
32ThefactthatonlypartofSCCsarepositiveforRUNX1
Figure 8 RUNX1 expression is deregulated in BCCs and SCCs. (a and b) Sections of parafﬁn-embedded specimens from human BCCs (a) and SCCs (b) were stained
withananti-RUNX1polyclonalantibody.Thesquaresrepresenttheareasofmagniﬁcationcontainingthetumorsshownintheinset.FortheBCCsection(a),themagniﬁcation
shows a higher RUNX1 staining in the tumor than in the basal layer of the surrounded epidermis. For the SCC section (b), the upper panel shows a negative specimen for
RUNX1 staining and the lower panel shows a positive one. Scale bar¼50mm. (c) RUNX1 expression is semiquantitatively assessed in 18 BCCs and 15 SCCs;  :n o
staining; þ: low, þþ: moderate, þþþ: strong staining
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insults and may be linked in particular with differential p53
mutations.
In summary, we present evidence that RUNX1 TF expres-
sion is regulated by a functional interplay between DNp63 and
p53, and that RUNX1 is involved in the control of the transition
between proliferation and early differentiation in human
keratinocytes. The use of large-scale genomic approaches
such as ChIP-chip or ChIP-seq would be of great interest for
identifying novel RUNX1 target genes in proliferating versus
differentiated keratinocytes in order to elucidate its role in the
regulation of epidermal homeostasis.
Materials and Methods
Cell cultures. HPK, isolated from neonatal foreskin, are cultured in KGM2
medium (PromoCell, Heidelberg, Germany) as previously described.
38 This study
was approved by the ethical research committee ‘Comite ´ de Protection des
Personnes Sud-Est-II’ (CODECOH Number DC-2008-262). A written informed
consent was obtained from infants’ parents according to the French bioethical law
of 2004 (loi 94–654, 29/07/1994) and the guidelines of the Helsinki Declaration.
HEK293 cells (provided by Pr. Arrigo, CNRS, Lyon), were cultured in DMEM 10%
(V/V) fetal bovine serum (Lonza). Differentiation of HPK or HaCaT cells was
induced by a shift to high calcium concentration (1.8mM) after culture at low
Ca
2þ concentration (0.06mM) up to conﬂuence. To analyze the proliferating
state, keratinocytes were transfected at 40% of conﬂuency and collected before
conﬂuency. To study the differentiating state, keratinocytes were transfected
at 90% of conﬂuency and collected at the beginning of differentiation.
Transient transfection. RUNX1 was overexpressed using JetPei
transfection (PolyPlus, Illkirch, France) with 1mg of pCiNeo-RUNX1 or pCMV-
RUNX1 (provided by Dr. Mouchiroud, CNRS, Lyon) following the manufacturer’s
instructions. For silencing experiments, keratinocytes were transfected at 20nM
ﬁnal concentration using Hyperfect transfection reagent (Qiagen, Germantown,
MD, USA) according to the manufacturer’s directions. siRNA sequences are listed
in Supplementary Table 1.
Real-time RT-PCR. Total RNA was extracted with the RNAeasy mini-kit
(Qiagen), reverse-transcribed into cDNA by MuLV reverse-transcriptase (Fermen-
tas, Waltham, MA, USA) and analyzed by real-time PCR using the Absolute Blue
QPCR SYBRGreen Rox mix (ThermoScientiﬁc, Waltham, MA, USA) on a
MX3000P real-time PCR system (Stratagene, Santa Clara, CA, USA) with the
primers shown in Supplementary Table 2. Results were obtained from
independent experiments using keratinocytes from three different donors run in
triplicates and were normalized to the 18S rRNA expression level.
Western blot, immunoﬂuorescence and immunohistochemistry.
Protein extraction and blotting were performed as described.
39 Actin was used as a
loading control. Results were obtained from three independent experiments with
different donors. Immunohistochemistry was done as previously described.
38
Antibodies are listed in Supplementary Table 3.
Proliferation assay and cell cycle analysis. For proliferation assay,
BrdU was added or not to the medium. The incorporated BrdU amount
was determined 6h later by the Cell Proliferation ELISA BrdU colorimetric
assay (Millipore, Darmstadt, Germany) according to the manufacturer’s instruc-
tions using a plate reader (Victor3, Perkin Elmer, Waltham, MA, USA). The
proliferation extent was expressed as OD mean values in the presence of BrdU—
OD mean values without BrdU±S.D. of triplicate wells. Keratinocyte cell cycle
progress was examined 24h after RUNX1 or control siRNA transfection using
FITC-BrdU/7-aminoactinomycin D Flow Kit (BD Pharmingen, Franklin Lakes, NJ,
USA) according to the manufacturer’s protocol. Fluorescence analysis was
performed on a FACS Calibur using Cellquest software (BD Biosciences, Franklin
Lakes, NJ, USA).
Chromatin immunoprecipitation. Equivalent numbers of HPK in a
proliferative or 3-day differentiated state were lysed after crosslinking with 1%
formaldehyde (Sigma, St. Louis, MO, USA). Chromatin was sheared by sonication,
precleared with proteinG-agarose/salmon sperm DNA beads (Upstate, Darmstadt,
Germany) and control immunoglobulins (Zymed, South San Francisco, CA,
USA), incubated overnight at 41C with 2mg anti-p63 4a4 (sc-8431 Santa Cruz,
Santa Cruz, CA, USA), anti-p53 DO-1 (sc-126 Santa Cruz) or control mouse
immunoglobulins. Immune complexes were collected with proteinG-agarose/
salmon sperm DNA beads, washed, extracted in 1% SDS, 0.1M NaHCO3 and
treated with RNAse A and proteinase K. Protein crosslink was reverted by heating
at 651C for at least 5h. DNA was puriﬁed using Qiaquick PCR-Puriﬁcation Kit
(Qiagen). QPCR were performed on the immunoprecipitated genomic DNA by
using speciﬁc primers listed in Supplementary Table 4.
Promoter analysis. 50 regulatory sequences ( 750, þ250 from TSS)
were retrieved from the promoter database at http://rulai.cshl.edu/cgi-bin/TRED/
and screened for RUNX1 consensus sites using the MatInspector promoter
analysis tool. For reporter gene assay, 251bp of human RUNX1 intron 5 or 312bp
of RUNX1 exon 1 were cloned by PCR ligation into the pGL3 promoter vector
(Promega, Madison, WI, USA) upstream of SV40 promoter. The KRT1 ( 846/
þ257) and LOR ( 1370/þ9) promoter segments were cloned into pGL4-basic
vector (Promega). Deletion of the distal (D) or proximal (P) RUNX1 binding sites
was performed by PCR/digestion from the full KRT1 promoter into pGL4-basic
vector to construct the P-site KRT1 promoter ( 546/þ257) and the D-site KRT1
promoter ( 846/þ28) vectors, respectively. Transient transfections were carried
out four times in duplicate on HEK293 cells using JetPei reagent (Polyplus).
Luciferase assays were performed using Dual-Luciferase Reporter Assay System
(Promega) according to the manufacturer instructions. The ratio of luciferase
activity for intron5-pGL3 promoter and exon1-pGL3 promoter was calculated 24h
after transfection with empty pCMV, pCMV-p53, empty pcDNA3 or pcDNA3-
DNp63
40 relative to pGL3 promoter empty vector. For RUNX1 transfections, the
luciferase activity ratio was calculated 24h after transfection by pCMV-CBFb,
pCMV-RUNX1 or both relative to pGL4-basic empty vector. Data were normalized
to the transfection efﬁciency assessed by pCMV-RL vector cotransfection.
Statistical analysis. All data are represented as a mean for at least three
experiments. Statistical signiﬁcance was calculated by a two-tailed Student’s t-test
for unpaired samples. Mean differences were considered to be signiﬁcant when
Po0.05 (*Po0.05; **Po0.01; ***Po0.001; ns, not signiﬁcant).
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